2
Clinical Trials associated with EBV GP350 CAR-T-cell therapy(Guangzhou Bioresette Biomedical Technology Co., Ltd.)To Investigate the Safety and Preliminary Efficacy of EBV CAR-T Cells in the Treatment of Relapsed/Refractory EBV-positive Nasopharyngeal Carcinoma
The aim of this study is to investigate the safety and preliminary efficacy of EBV CAR-T cells in the treatment of relapsed/refractory NPC
Clinical study of safety and preliminary efficacy of EBV CAR-T/TCR-T cells in patients with relapsed/refractory EBV positive lymphoma/nasopharyngeal carcinoma
100 Clinical Results associated with EBV GP350 CAR-T-cell therapy(Guangzhou Bioresette Biomedical Technology Co., Ltd.)
100 Translational Medicine associated with EBV GP350 CAR-T-cell therapy(Guangzhou Bioresette Biomedical Technology Co., Ltd.)
100 Patents (Medical) associated with EBV GP350 CAR-T-cell therapy(Guangzhou Bioresette Biomedical Technology Co., Ltd.)
100 Deals associated with EBV GP350 CAR-T-cell therapy(Guangzhou Bioresette Biomedical Technology Co., Ltd.)